StreetInsider.com News Articles

Form 4 Oric Pharmaceuticals, For: Aug 26 Filed by: Piscitelli Dominic

Fri, 28 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26998006.html

Form 4 Oric Pharmaceuticals, For: Aug 26 Filed by: Piscitelli Dominic

Fri, 28 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26998006.html

Form 144 Oric Pharmaceuticals, Filed by: Piscitelli Dominic

Wed, 26 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26981811.html

Form 144 Oric Pharmaceuticals, Filed by: Piscitelli Dominic

Wed, 26 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260826/26981811.html

ORIC Pharmaceuticals (ORIC) PT Raised to $27 at H.C. Wainwright

Mon, 10 Aug 2026 06:53:38 -0400

(Updated - August 10, 2026 6:53 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $27.00 (from $25.00) while maintaining a Buy rating.

The analyst commented: "As we look into 2H26, we note a catalyst-rich year for ORIC, which includes: (1) a program update for ORIC-944 in 2H26 (see our prior note for our thoughts on the dose-optimization results released earlier this year); (2) presentation of updated data for enozertinib monotherapy in 1L EGFR exon 20 insertion-positive NSCLC and initial results for the combination with subcutaneous amivantamab in 2H26. Recall, per the December 2025

ORIC Pharmaceuticals (ORIC) PT Raised to $27 at H.C. Wainwright

Mon, 10 Aug 2026 06:53:38 -0400

(Updated - August 10, 2026 6:53 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $27.00 (from $25.00) while maintaining a Buy rating.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:30:00 -0400

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 3, 2026 (the “Grant Date”), ORIC granted a total of 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees who began their employment with ORIC in July 2026.

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:30:00 -0400

These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each

ORIC Pharmaceuticals, Inc. (ORIC) Misses Q2 EPS by 2c

Mon, 03 Aug 2026 16:46:12 -0400

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported Q2 EPS of ($0.38), $0.02 worse than the analyst estimate of ($0.36).

For earnings history and earnings-related data on ORIC Pharmaceuticals, Inc. (ORIC) click here.

Form 10-Q Oric Pharmaceuticals, For: Jun 30

Mon, 03 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260803/26858279.html

Form 10-Q Oric Pharmaceuticals, For: Jun 30

Mon, 03 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260803/26858279.html

Form 8-K Oric Pharmaceuticals, For: Aug 03

Mon, 03 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260803/26857908.html

Form 8-K Oric Pharmaceuticals, For: Aug 03

Mon, 03 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260803/26857908.html

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Mon, 03 Aug 2026 16:05:00 -0400

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone

Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1

Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial

Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 03, 2026

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Mon, 03 Aug 2026 16:05:00 -0400

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone

Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1

Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial

Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 03, 2026

Form S-8 Oric Pharmaceuticals,

Thu, 30 Jul 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260730/26844918.html

Form S-8 Oric Pharmaceuticals,

Thu, 30 Jul 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260730/26844918.html

Form 8-K Oric Pharmaceuticals, For: Jul 28

Thu, 30 Jul 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260730/26844526.html

Form 8-K Oric Pharmaceuticals, For: Jul 28

Thu, 30 Jul 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260730/26844526.html

Form 4 Oric Pharmaceuticals, For: Jul 24 Filed by: Heyman Richard A.

Tue, 28 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260728/26827332.html

Form 4 Oric Pharmaceuticals, For: Jul 24 Filed by: Heyman Richard A.

Tue, 28 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260728/26827332.html

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Mon, 20 Jul 2026 08:30:00 -0400

Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC

Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone

Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance,

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Mon, 20 Jul 2026 08:30:00 -0400

Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC

Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone

Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC

ORIC Pharmaceuticals starts Phase 3 trial for prostate cancer drug

Tue, 14 Jul 2026 16:05:13 -0400

ORIC Pharmaceuticals (Nasdaq: ORIC) announced the initiation of its Himalayas-1 global Phase 3 registrational trial evaluating rinzimetostat in patients with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with abiraterone, according to a company statement dated July 14, 2026.

The trial is expected to enroll approximately 600 patients across more than 250 sites in 25 countries. Patients will be randomized 1:1 to receive 400 mg once daily rinzimetostat in combination with darolutamide, versus physician's choice of an androgen receptor inhibitor or docetaxel. The primary endpoint is radiographic progression-free survival, with overall survival as the key secondary endpoint.

Alongside the trial initiation,

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

Tue, 14 Jul 2026 16:05:00 -0400

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone

Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone and